Raltegravir

Overview

Raltegravir is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL254316).

API suppliers (1)

Suppliers of Raltegravir backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• Lupin LimitedIndia

Patent & exclusivity (US)

Per the FDA Orange Book (6 approved US products), the latest listed US patent on Raltegravir expires 29 Mar 2032. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

N-[2-[4-[(4-fluorophenyl)methylcarbamoyl]-5-hydroxy-1-methyl-6-oxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide

Canonical SMILES

CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F

InChIKey

CZFFBEXEKNGXKS-UHFFFAOYSA-N